ArticleScientific reports2018
Increased intracellular activity of MP1102 and NZ2114 against Staphylococcus aureus in vitro and in vivo.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Designing, Synthesis and In Vitro Antimicrobial Activity of Peptide Against Biofilm Forming Methicillin Resistant Staphylococcus aureus.Current microbiology · 2025Article
- Expression and characterization of the new antimicrobial peptide AP138L-arg26 anti Staphylococcus aureus.Applied microbiology and biotechnology · 2024Article
- Recent Advances of Cell-Penetrating Peptides and Their Application as Vectors for Delivery of Peptide and Protein-Based Cargo Molecules.Pharmaceutics · 2023Review
- Molecular Modification of Kex2 P1' Site Enhances Expression and Druggability of Fungal Defensin.Antibiotics (Basel, Switzerland) · 2023Article
- Prediction and bioactivity of small-molecule antimicrobial peptides fromFrontiers in microbiology · 2023Article
- Plectasin: from evolution to truncation, expression, and better druggability.Frontiers in microbiology · 2023Article
- Editorial: Community series in antimicrobial peptides: Molecular design, structure function relationship and biosynthesis optimization.Frontiers in microbiology · 2023Article
- Fracture-related infection.Nature reviews. Disease primers · 2022Review
- C-terminal mini-PEGylation of a marine peptide N6 had potent antibacterial and anti-inflammatory properties against Escherichia coli and Salmonella strains in vitro and in vivo.BMC microbiology · 2022Article
- Antibacterial peptide NZ2114-loaded hydrogel accelerates Staphylococcus aureus-infected wound healing.Applied microbiology and biotechnology · 2022Article
- Non-antibiotic strategies for prevention and treatment of internalizedFrontiers in microbiology · 2022Review
- Pharmacokinetics and Pharmacodynamics of Fungal Defensin NZX AgainstFrontiers in microbiology · 2022Article
- Effect of NZ2114 againstFrontiers in microbiology · 2022Article
- Editorial: Antimicrobial Peptides: Molecular Design, Structure-Function Relationship, and Biosynthesis Optimization.Frontiers in microbiology · 2022Article
- Ginsenoside 20(S)-Rh2 promotes cellular pharmacokinetics and intracellular antibacterial activity of levofloxacin against Staphylococcus aureus through drug efflux inhibition and subcellular stabilization.Acta pharmacologica Sinica · 2021Article
- Intracellular escape strategies of Staphylococcus aureus in persistent cutaneous infections.Experimental dermatology · 2021Review
- Design and Pharmacodynamics of Recombinant Fungus Defensin NZL with Improved Activity againstInternational journal of molecular sciences · 2021Article
- Potent intracellular antibacterial activity of a marine peptide-N6NHApplied microbiology and biotechnology · 2021Article
- Deciphering the Antibacterial Role of Peptide FromFrontiers in microbiology · 2021Article
- Marine Peptide-N6NH2 and Its Derivative-GUON6NH2 Have Potent Antimicrobial Activity Against IntracellularFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of Staphylococcus aureus infections remains very difficult due to its capacity to survive intracellularly and its multidrug resistance. In this study, the extracellular/intracellular activities of plectasin derivatives-MP1102/NZ2114 were investigated against three methicillin-susceptible/-resistant S. aureus (MSSA/MRSA) strains in RAW 264.7 macrophages and mice to overcome poor intracellular activity. Antibacterial activities decreased 4-16-fold under a mimic phagolysosomal environment. MP1102/NZ2114 were internalized into the cells via clathrin-mediated endocytosis and macropinocytosis and distributed in the cytoplasm; they regulated tumor necrosis factor-α, interleukin-1β and interleukin-10 levels. The extracellular maximal relative efficacy (E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.